Tirzepatide and Cancer Risk

Introduction: Tirzepatide, a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, has revolutionized the management of type 2 diabetes and obesity. Due to its widespread use and chronic nature of treatment, assessing its long-term safety, particularly concerning cancer risk, is crucial. This descriptive review investigates existing research on the association between Tirzepatide use and cancer development. Methodology: A review of published articles, including a meta-analysis of randomized controlled trials (RCTs), a retrospective analysis of the FDA Adverse Event Reporting System (FAERS) database, and peer-reviewed articles, was conducted, focusing on data from the last five years. Results: Reviewed RCTs, primarily designed to evaluate efficacy, showed no significant increase in overall cancer events. Cases of pancreatitis were rare and evenly distributed between Tirzepatide and placebo groups in trials like SURMOUNT and SURPASS. Although some studies reported transient, reversible elevations in pancreatic enzymes, long-term follow-up studies specifically designed to assess pancreatic cancer risk are lacking, and the established link between chronic pancreatitis and pancreatic cancer necessitates caution. Regarding thyroid cancer, current evidence from RCTs and meta-analyses, along with FAERS data, does not conclusively link Tirzepatide to an increased risk. In conclusion, while Tirzepatide demonstrates remarkable efficacy in weight loss and glycemic control, current research, primarily from short-to-medium-term clinical trials not specifically powered for cancer outcomes, shows no firm evidence of an increased cancer risk. Future RCTs with cancer risk as a primary outcome are essential to provide more definitive insights into the long-term safety profile of Tirzepatide.